117 related articles for article (PubMed ID: 4066222)
41. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
42. Mafosfamide (ASTA-Z-7654) in vitro treatment of bone marrow does not eradicate Philadelphia-positive cells in chronic myeloid leukaemia.
Mortensen BT; Ernst P; Philip P
Eur J Haematol; 1988 Sep; 41(3):218-22. PubMed ID: 3181395
[TBL] [Abstract][Full Text] [Related]
43. N3-methyl-mafosfamide as a chemically stable, alternative prodrug of mafosfamide.
Moon KY; Kwon CH
Bioorg Med Chem Lett; 1998 Jul; 8(13):1673-8. PubMed ID: 9873412
[TBL] [Abstract][Full Text] [Related]
44. Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.
Moriconi WJ; Taylor S; Slavik M; Belt RJ; Haas CD; Hoogstraten B
Invest New Drugs; 1985; 3(1):57-62. PubMed ID: 3157661
[TBL] [Abstract][Full Text] [Related]
45. Experimental toxicology of ASTA Z 7557 (INN mafosfamide).
Pohl J; Hilgard P; Jahn W; Zechel HJ
Invest New Drugs; 1984; 2(2):201-6. PubMed ID: 6469515
[TBL] [Abstract][Full Text] [Related]
46. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
[TBL] [Abstract][Full Text] [Related]
47. Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion.
Khayat D; Borel C; Azab M; Paraisot D; Malaurie E; Bouloux C; Weil M
Cancer Chemother Pharmacol; 1992; 30(3):226-8. PubMed ID: 1628372
[TBL] [Abstract][Full Text] [Related]
48. Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).
Weiss L; Slavin G; Reich S; Sidi H; Slavin S
Bone Marrow Transplant; 1994 Jan; 13(1):27-30. PubMed ID: 8019450
[TBL] [Abstract][Full Text] [Related]
49. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC
Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
[TBL] [Abstract][Full Text] [Related]
50. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
[TBL] [Abstract][Full Text] [Related]
51. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC
Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899
[No Abstract] [Full Text] [Related]
52. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
[TBL] [Abstract][Full Text] [Related]
53. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
Makrynikola V; Kabral A; Bradstock KF
Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
[TBL] [Abstract][Full Text] [Related]
54. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.
Voelcker G; Bielicki L; Hohorst HJ
J Cancer Res Clin Oncol; 1997; 123(11-12):623-31. PubMed ID: 9620221
[TBL] [Abstract][Full Text] [Related]
55. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC
Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404
[TBL] [Abstract][Full Text] [Related]
56. Phase-I study of alpha-1,3,5-triglycidyl-s-triazinetrione (NSC 296934).
Dombernowsky P; Lund B; Hansen HH
Cancer Chemother Pharmacol; 1983; 11(1):59-61. PubMed ID: 6883626
[TBL] [Abstract][Full Text] [Related]
57. Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial.
Pannier D; Adenis A; Bogart E; Dansin E; Clisant-Delaine S; Decoupigny E; Lesoin A; Amela E; Ducornet S; Meurant JP; Le Deley MC; Penel N
BMC Cancer; 2018 Jul; 18(1):775. PubMed ID: 30064401
[TBL] [Abstract][Full Text] [Related]
58. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
59. Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism.
Kwon CH; Borch RF; Engel J; Niemeyer U
J Med Chem; 1987 Feb; 30(2):395-9. PubMed ID: 3806619
[TBL] [Abstract][Full Text] [Related]
60. Influence of low doses of an oxazaphosphorine on natural killer activity of human lymphocytes.
Blomgren H
Cancer Immunol Immunother; 1989; 29(2):151-3. PubMed ID: 2720708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
